CVD at different stages: (1) (early) risk to develop CVD, irrespectively if treated or not
Conditions
Interventions
Group 1: Four country-specific Patient Panels from different European countries (Belgium, Germany, Ireland, United Kingdom), each consisting of 10-12 patients. Patient Panel Members are patients acros
Sponsors
Deutsche Stiftung für chronisch Kranke
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients - Be at risk to develop a CVD or diagnosis of a CVD - Ability to participate in in-person meetings - Willingness to participate in a Patient Panel - Ability to give informed consent Relatives participating in a Patient Panel as a representative of a patient with CVD, must be actively involved in their care and fulfil the same inclusion criteria as patients (except “be at risk to develop a CVD or diagnosis of a CVD”). Healthcare professionals - Profession in the CVD sector - Ability and willingness to participate
Exclusion criteria
Exclusion criteria: Patients and relatives - Serious cognitive impairment - Insufficient language skills Healthcare professionals - Insufficient language skills - Insufficient technological skills - No access to a device with internet connection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identify preferences, experiences, requirements, and needs for better diagnosis, treatment, and self-care in CVD from the per-spective of patients. The focus will be on (1) building tailored sets of Patient Reported Outcome Measures (PROMs) and Patient Reported Experience Measures (PREMs) appropriate for different patient populations, (2) developing motivational frameworks/models to increase treatment and technology adherence, and (3) testing the usability and acceptability of a new digital tool. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identify preferences, experiences, and needs for better diagnosis, treatment, and self-care in CVD from the perspective of healthcare professionals (HCPs). The focus will be on (1) building tailored sets of PROMs and PREMs appropriate for different patient populations, and (2) developing motivational frameworks/models to increase treat-ment and technology adherence of patients. | — |
Countries
Germany, Ireland, Netherlands, United Kingdom
Contacts
Public ContactBettina Zippel-Schultz
Deutsche Stiftung für chronisch Kranke
Outcome results
None listed